ACM

Aisling Capital Management Portfolio holdings

AUM $360M
This Quarter Return
+44.95%
1 Year Return
+114.67%
3 Year Return
+1,171.46%
5 Year Return
+892.24%
10 Year Return
–
AUM
$335M
AUM Growth
+$335M
Cap. Flow
-$829K
Cap. Flow %
-0.25%
Top 10 Hldgs %
98.51%
Holding
17
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

1
SYRE icon
Spyre Therapeutics
SYRE
$829K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$9.89B
$245M 73.07%
6,068,125
– –
VRNA
2
Verona Pharma
VRNA
$9.16B
$22.2M 6.61%
1,115,352
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.41B
$22.2M 6.61%
1,025,000
– –
BMEA icon
4
Biomea Fusion
BMEA
$116M
$11.6M 3.46%
798,757
– –
CMPS
5
Compass Pathways
CMPS
$424M
$8.44M 2.52%
964,500
– –
GLUE icon
6
Monte Rosa Therapeutics
GLUE
$296M
$8.32M 2.48%
1,472,331
– –
NUVB icon
7
Nuvation Bio
NUVB
$1.02B
$3.84M 1.14%
2,541,009
– –
SPRB
8
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
$3.53M 1.05%
1,205,511
– –
PSTX
9
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.51M 1.05%
1,043,267
– –
MRKR icon
10
Marker Therapeutics
MRKR
$12M
$1.73M 0.52%
314,286
– –
ELEV
11
DELISTED
Elevation Oncology
ELEV
$1.52M 0.45%
2,834,910
– –
OKUR
12
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
$1.42M 0.42%
886,075
– –
TECX
13
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
$1.37M 0.41%
1,009,779
– –
ACRS icon
14
Aclaris Therapeutics
ACRS
$209M
$456K 0.14%
434,455
– –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$164K 0.05%
288,571
– –
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$51.2K 0.02%
387,653
– –
SYRE icon
17
Spyre Therapeutics
SYRE
$996M
– –
-67,645
Closed -$829K